 |
|
|
| |
48 Week Study of the First PI-based Single Tablet-Regimen (STR)
Darunavir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF)
vs.
Darunavir (DRV) boosted by Cobicistat (COBI) and Emtricitabine/Tenofovir
Disoproxil Fumarate (TVD) in HIV-Infected Treatment-Naïve Adults
|
| |
| |
Reported by Jules Levin
ICAAC 2014
September 5-9, 2014, Washington, DC
Anthony Mills1, Roberto Ortiz2,Gordon Crofoot, Jr.3, Cheryl McDonald4, Peter Shalit5, Jason Flamm6, David Shamblaw7, Michael Saag8, Huyen Cao9, Hal Martin9, Moupali Das9, Hui Liu9, Lijie Zhong9, Christian Callebaut9, Joseph Custodio9, Andrew Cheng9, Scott McCallister9.
1Southern California Men's Medical Group, Los Angeles, CA, 2 Orlando Immunology Center, Orlando, FL, 3 Gordon Crofoot MDPA, Houston, TX, 4Tarrant County Infectious Disease Associates, Forth Worth, TX, 5 University of Washington, Seattle, WA, 6 Kaiser Permanente, Sacramento, CA, 7 La Playa Medical Group and Clinical Research, San Diego, CA., 8University of Alabama, Birmingham, AL, and 9Gilead Sciences, Inc., Foster City, CA.
|
| |
|
|
|
|
|
